2025 Annual Report and Notice of AGM

Summary by AI BETAClose X

HUTCHMED (China) Limited has announced that its 2025 Annual Report and Notice of Annual General Meeting will be distributed to shareholders on April 10, 2026, and will also be available on the company's website. The 2026 Annual General Meeting will be held as an electronic/hybrid meeting on May 12, 2026, at 4:00 pm Hong Kong Time. The company is an innovative, commercial-stage biopharmaceutical company focused on developing targeted therapies and immunotherapies for cancer and immunological diseases.

Disclaimer*

Hutchmed (China) Limited
09 April 2026
 

2025 Annual Report and Notice of Annual General Meeting

 

Hong Kong, Shanghai & Florham Park, NJ - Thursday, April 9, 2026: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13) today announces that its 2025 Annual Report, together with the Notice of Annual General Meeting and the Form of Proxy ("AGM Materials"), will be posted on April 10, 2026 to those shareholders who have elected to receive the AGM Materials in printed form. The documents can also be accessed from the HUTCHMED website (www.hutch-med.com).

 

The 2026 Annual General Meeting ("AGM") will be an electronic/hybrid meeting to be held at 1st Floor, Harbour Grand Kowloon, 20 Tak Fung Street, Hung Hom, Kowloon, Hong Kong on Tuesday, May 12, 2026 at 4:00 pm Hong Kong Time (9:00 am London Time), with electronic access through an online platform as detailed in the AGM Materials.

 

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch‑med.com or follow us on LinkedIn.

 

CONTACTS

Investor Enquiries

+852 2121 8200 / ir@hutch-med.com



Media Enquiries


FTI Consulting -

+44 20 3727 1030 / HUTCHMED@fticonsulting.com

   Ben Atwell / Tim Stamper

   +44 7771 913 902 (Mobile) / +44 7779 436 689 (Mobile)

Brunswick - Zhou Yi

+852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com



Panmure Liberum

Nominated Advisor and Joint Broker

Atholl Tweedie / Emma Earl / Rupert Dearden

+44 20 7886 2500



Cavendish

Joint Broker

Geoff Nash / Nigel Birks

+44 20 7220 0500



Deutsche Numis

Joint Broker

Freddie Barnfield / Jeffrey Wong / Duncan Monteith

+44 20 7260 1000

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings